Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Mole101on Jun 15, 2021 12:40pm
179 Views
Post# 33388881

RE:Game Plan

RE:Game Plan

June 7 th was the FDA decision  on Biogen and today is the 15th , so basically 8 days have gone by, We are not baking bread in here ,  If you expect a quick ramp up into PH1 you're setting yourself for disappointment, The process is slow and boring but the expectation of results will be explosive. AGM is couple of weeks away, maybe something else comes out before but who knows, I'll be happy to hear about the ALS program and maybe for them yo elaborate more on the Serology program . I would agree that now is time to accumulate again .. 



quote=Annayya]We need our highly paid and skilled executives to act on their game plan right away. PMN can't be a penny stock for too long with our Boston investors stating that one of their priority is to list on NASDAQ. What I am counting on is for some great news on phase 1 PMN310 partnership followed by more good news to firmly place the SP at a price high enough (over 60 cents) so the warrants will expire within the 20 day clause. This will prevent further PPs as the investors will definitely be more inclined now to exercise their warrants. There's no excuses for delays, now that aducanumab is approved. The serology test news would be a nice bonus, but it seems like it's taking forever to finalize. I can't believe that they let the SP fall back to 21 cents. It's ridiculous![/quote]
 

<< Previous
Bullboard Posts
Next >>